JANX insider buying – Janux Therapeutics, Inc.
8 insider purchases since 2016 worth $163.9M by 7 different insiders. Last 12 months: 0 purchases, $0. Most recent filing: 2025-03-07.
Same time range as the chart above - each mark sits under the week of the trade. Circles = purchases (height = price paid, size = amount), red triangles = open-market sales of $50k+. Prices as reported, not adjusted for later stock splits.
Purchases are open-market buys (SEC Form 4, code "P") - insiders paying with their own money. Sales are open-market sales (code "S") of $50,000 or more; many sales are pre-planned (Rule 10b5-1) or made for taxes and diversification. Each row links to the original filing.
Bought, sold, still holding?
| Insider | Bought | First / last buy | Sold since 2016 | Holds now* | Status |
|---|---|---|---|---|---|
| Kolchinsky Peter Director | $53.7M 1× · 1,200,000 sh | 2024-10-18 2024-10-18 | – | 9,317,246 shares as of 2024-10-22 | Holds - never sold |
| RA CAPITAL MANAGEMENT, L.P. Director | $50.0M 1× · 2,941,176 sh | 2021-06-15 2021-06-15 | – | 2,500 shares as of 2024-06-28 | Holds - never sold |
| RA Capital Healthcare Fund LP Director | $25.3M 1× · 824,041 sh | 2025-03-05 2025-03-05 | – | 6,250 shares as of 2025-06-13 | Holds - never sold |
| Avalon Ventures XI, L.P. 10% Owner | $15.7M 2× · 1,479,265 sh | 2021-06-15 2023-11-13 | 1× · $82.1M last 2024-06-03 | 7,244,907 shares as of 2024-06-05 | Sold part |
| ORBIMED ADVISORS LLC Director | $12.0M 1× · 705,853 sh | 2021-06-15 2021-06-15 | – | 2,760,366 shares as of 2021-06-16 | Holds - never sold |
| RA Capital Nexus Fund II, L.P. Director | $6.2M 1× · 495,008 sh | 2023-07-19 2023-07-19 | – | 11,750 shares as of 2026-06-12 | Holds - never sold |
| Bregua Corp 10% Owner | $999,991 1× · 58,823 sh | 2021-06-15 2021-06-15 | – | 3,749,250 shares as of 2021-06-16 | Holds - never sold |
* Shares held after the insider's most recent SEC filing for this company (all share classes, direct and indirect). If an insider stops filing, later changes are not known.
Insider buying and selling by year
| Year | Purchases | Bought | Buyers | Sales | Sold |
|---|---|---|---|---|---|
| 2026 | 0 | – | – | 2 | $167,777 |
| 2025 | 1 | $25.3M | 1 | 9 | $2.2M |
| 2024 | 1 | $53.7M | 1 | 14 | $259.3M |
| 2023 | 2 | $11.2M | 2 | – | – |
| 2021 | 4 | $73.7M | 4 | 3 | $10.6M |
Insider purchases
| Filed | Insider | Role | Shares | Avg price | Value | Holdings | Filing |
|---|---|---|---|---|---|---|---|
| 2025-03-07 | RA Capital Healthcare Fund LP | Director | 824,041 | $30.75 | $25.3M | +8.8% | SEC |
| 2024-10-22 | Kolchinsky Peter | Director | 1,200,000 | $44.75 | $53.7M | +14.8% | SEC |
| 2023-11-13 | Avalon Ventures XI, L.P. | 10% Owner | 849,854 | $5.87 | $5.0M | SEC | |
| 2023-07-21 | RA Capital Nexus Fund II, L.P. | Director | 495,008 | $12.46 | $6.2M | +6.5% | SEC |
| 2021-06-16 | RA CAPITAL MANAGEMENT, L.P. | Director | 2,941,176 | $17.00 | $50.0M | +62.8% | SEC |
| 2021-06-16 | ORBIMED ADVISORS LLC | Director | 705,853 | $17.00 | $12.0M | +34.4% | SEC |
| 2021-06-16 | Bregua Corp | 10% Owner | 58,823 | $17.00 | $999,991 | +1.6% | SEC |
| 2021-06-16 | Avalon Ventures XI, L.P. | 10% Owner | 629,411 | $17.00 | $10.7M | +16.3% | SEC |
Insider sales
| Filed | Insider | Role | Shares | Avg price | Value | Type | Filing |
|---|---|---|---|---|---|---|---|
| 2026-06-04 | Doyle Janeen Noel | Officer | 4,059 | $14.03 | $56,948 | Sale | SEC |
| 2026-01-02 | Campbell David Alan | CEO | 8,072 | $13.73 | $110,829 | Sale | SEC |
| 2025-12-03 | Meyer Andrew Hollman | Officer | 3,333 | $32.98 | $109,913 | Pre-planned (10b5-1) | SEC |
| 2025-11-14 | Meyer Andrew Hollman | Officer | 3,333 | $30.00 | $99,990 | Pre-planned (10b5-1) | SEC |
| 2025-10-30 | Meyer Andrew Hollman | Officer | 16,665 | $30.06 | $500,950 | Pre-planned (10b5-1) | SEC |
| 2025-05-02 | Meyer Andrew Hollman | Officer | 3,333 | $32.03 | $106,749 | Pre-planned (10b5-1) | SEC |
| 2025-04-23 | Meyer Andrew Hollman | Officer | 3,334 | $30.00 | $100,020 | Pre-planned (10b5-1) | SEC |
| 2025-03-05 | Meyer Andrew Hollman | Officer | 3,334 | $32.14 | $107,162 | Pre-planned (10b5-1) | SEC |
| 2025-02-05 | Meyer Andrew Hollman | Officer | 3,334 | $42.29 | $141,010 | Pre-planned (10b5-1) | SEC |
| 2025-01-08 | Campbell David Alan | CEO | 5,000 | $60.00 | $300,000 | Pre-planned (10b5-1) | SEC |
| 2025-01-03 | Meyer Andrew Hollman | Officer | 13,334 | $54.88 | $731,792 | Sale | SEC |
| 2024-12-27 | Campbell David Alan | CEO | 25,000 | $56.19 | $1.4M | Pre-planned (10b5-1) | SEC |
| 2024-12-03 | Campbell David Alan | CEO | 15,000 | $67.00 | $1.0M | Pre-planned (10b5-1) | SEC |
| 2024-11-27 | Campbell David Alan | CEO | 25,000 | $51.59 | $1.3M | Pre-planned (10b5-1) | SEC |
| 2024-10-30 | Campbell David Alan | CEO | 25,000 | $53.54 | $1.3M | Pre-planned (10b5-1) | SEC |
Showing the latest 15 of 28 sales of $50,000+ since 2016.
Compiled automatically from public SEC filings. Not investment advice. Get every new insider purchase in the daily report.
Get every new insider purchase the day it's filed
Daily report with all SEC insider buys, cluster buys, company events and the crypto money-flow radar.
Get started free